Education
About Us
Working with TipRanks
Follow Us
reAlpha Tech Corp. (AIRE)
NASDAQ:AIRE
AIRE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $4.49
Previous CloseN/A
Volume398.68K
Average Volume (3M)178.67K
Market Cap
$61.25M
Enterprise Value$55.22M
Total Cash (Recent Filing)$4.84M
Total Debt (Recent Filing)$118.81K
Price to Earnings (P/E)―
Beta0.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,054,180
10 Day Avg. Volume99,374
30 Day Avg. Volume178,667
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)169.61
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.84
Enterprise Value/Ebitda-6.56
Forecast
1Y Price Target
$3.00Price Target Upside125.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
reAlpha Tech Corp. News
PremiumCompany Announcements
reAlpha Tech Corp. Resolves Disputes and Alters Financial Structure
PremiumCompany Announcements
reAlpha Tech Corp. Amends Sales Agreement in 2025
PremiumCompany Announcements
reAlpha Tech Corp. Expands with GTG Financial Acquisition
PremiumCompany Announcements
reAlpha Tech Corp. Unveils AI-Driven Homebuying StrategyPremiumCompany Announcements
reAlpha Tech Corp. Approves 2025 Incentive Plan
PremiumCompany Announcements
reAlpha Tech Corp. Appoints New CFO Amid Strategic Growth---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAIRE reported results that beat estimates on revenue, gross margin, and adjusted EBITDA, significantly topping the high-end of revenue guidance.
Growth ProspectsThe acquisition of GTG Financial expands reAlpha’s mortgage geographic footprint to 28 U.S. states, contributing materially to the top line.
Regulatory EnvironmentNew regulation allows negotiable commissions for buyer agents, making reAlpha's zero-commission platform an attractive solution.
Bears Say
Earnings EstimatesEstimates for 4Q24 were lowered after preannounced results came in lower than guidance and expectations.
Stock PerformanceThe stock price opened at $23.01 and closed at $406.67 after reaching a high of $575.41 on its first day of trading, but by the 10th day of trading, the stock closed at $8.99.
---
Options Prices
Currently, No data available
---
Ownership Overview
69.56% Insiders
0.37% Mutual Funds
0.04% Other Institutional Investors
29.25% Public Companies and
Individual Investors
AIRE FAQ
What was reAlpha Tech Corp.’s price range in the past 12 months?
reAlpha Tech Corp. lowest stock price was $0.53 and its highest was $4.49 in the past 12 months.
What is reAlpha Tech Corp.’s market cap?
reAlpha Tech Corp.’s market cap is $61.25M.
When is reAlpha Tech Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were reAlpha Tech Corp.’s earnings last quarter?
reAlpha Tech Corp. released its earnings results on Aug 14, 2024. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.03.
Is reAlpha Tech Corp. overvalued?
According to Wall Street analysts reAlpha Tech Corp.’s price is currently Undervalued.
Does reAlpha Tech Corp. pay dividends?
reAlpha Tech Corp. does not currently pay dividends.
What is reAlpha Tech Corp.’s EPS estimate?
reAlpha Tech Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does reAlpha Tech Corp. have?
reAlpha Tech Corp. has 46,054,180 shares outstanding.
What happened to reAlpha Tech Corp.’s price movement after its last earnings report?
reAlpha Tech Corp. reported an EPS of -$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6%.
Which hedge fund is a major shareholder of reAlpha Tech Corp.?
Currently, no hedge funds are holding shares in AIRE
---
reAlpha Tech Corp. Stock Smart Score
Company Description
reAlpha Tech Corp.
Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.
---
AIRE Stock 12 Month Forecast
Average Price Target
$3.00
▲(125.56% Upside)
Technical Analysis
Zillow Group Class C
―
Zillow Group Class A
―
eXp World Holdings
―
Redfin
―
Opendoor Technologies
―
Best Analysts Covering AIRE
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+11.63%
reiterated a buy rating 25 days ago
Copying Allen Klee's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +11.63% per trade.
---